PRED - Predictive Technology Group, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.5000
+0.2600 (+11.61%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.2400
Open2.2400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.0900 - 2.8500
52 Week Range0.7700 - 6.9100
Volume804,253
Avg. Volume568,545
Market Cap681.338M
Beta (3Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-0.0560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Predictive Technology Group Announces its 11th Consecutive Quarter of Revenue Growth

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the continuation of consecutive quarter revenue growth for the fiscal 2019 fourth quarter ended June 30, 2019.

  • Zacks Small Cap Research20 days ago

    PRED: Thermo Fisher Deal to Advance Endometriosis Research

    Over the last couple weeks Predictive Technology Group (PRED) has achieved two milestones in its advance towards validating and commercializing its endometriosis diagnostic test. As we discussed in our initiation, the disease impacts an estimated 200 million women worldwide, is frequently misdiagnosed and can be diagnosed early with Predictive’s genetic tests. Thermo Fisher’s collaboration with Predictive Laboratories is focused on studying the genetic factors underlying infertility in women.

  • GlobeNewswire23 days ago

    Predictive Technology Group Announces the Presentation of New Data Demonstrating the Genetic Basis of Endometriosis at ESHRE

    Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that data from a study of the genes underlying endometriosis may lead to new pathophysiology insights, improved diagnostics and novel treatment approaches. “Predictive Laboratories is committed to comprehensive disease management and advancing research into the genetic cause of endometriosis to improve the diagnosis and management of patients suffering from the disease,” said Bradley Robinson, CEO of Predictive Technology Group.

  • GlobeNewswire28 days ago

    Predictive Technology Group Announces the Presentation of New Genetic Findings in Endometriosis at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology

    SALT LAKE CITY, June 20, 2019 -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics.

  • PR Newswire29 days ago

    Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration

    Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment CARLSBAD, Calif. , June 19, 2019 ...

  • Zacks Small Cap Researchlast month

    PRED: Fertile Grounds for Genetic Testing

    Predictive Technology Group, Inc. (PRED) is a cellular therapy and genetic diagnostic testing company currently commercializing its portfolio of four placental and Wharton’s Jelly umbilical cord-derived allografts and two gene-based diagnostics. The cellular therapy division provides products derived from amniotic tissue and Wharton’s Jelly that are used by physicians in a variety of healing applications. Genetic diagnostic testing is focused on the women’s health market and is expected to commercialize and seek approval for a test specifically for endometriosis.

  • GlobeNewswirelast month

    Predictive Technology Group Names Industry Veteran Dr. Douglas Rabin Vice President of Medical Affairs, Women’s Health of Predictive Laboratories

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health. In this newly created position, he will provide critical medical affairs support for the women's health clinical franchise. Dr. Rabin has more than 25 years of experience in women's healthcare, including both clinical reproductive endocrinology, and obstetrics and gynecology.

  • GlobeNewswire2 months ago

    Predictive Technology Group Reports Third Quarter Fiscal 2019 Financial Results

    SALT LAKE CITY, May 21, 2019 -- Predictive Technology Group, Inc. (OTC PINK: PRED) (the Company), a leader in the use of data analytics for disease identification and.

  • GlobeNewswire2 months ago

    Predictive Biotech Signs Letter of Intent With IQVIA to Begin Clincial Trial for Osteoarthritis of the Knee

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces the signing of a letter of intent with IQVIA (Formerly Quintiles and IMS) to guide the regulatory strategy for its wholly owned subsidiary Predictive Biotech. This collaboration will accelerate the process of identifying and executing the appropriate regulatory pathways for the Company’s existing products and future product candidates. Specifically, IQVIA will guide Predictive Biotech in its U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application and subsequent clinical trial for osteoarthritis (OA) of the knee.

  • GlobeNewswire2 months ago

    Predictive Technology Group Finalizes Board Committee Chair Appointments

    SALT LAKE CITY , May 09, 2019 -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical.

  • GlobeNewswire2 months ago

    Predictive Technology Group Announces Enrollment Milestone of 200 Participants in Predictive Laboratories’ Study for Chronic Joint and Spine Pain

    The primary objective of the IRB study is to conduct genetic research related to healthcare advancement in the diagnosis, treatment and prevention of conditions causing chronic pain. The first 200 participants have volunteered for the study by submitting their DNA samples to the Predictive Biorepository and by reporting detailed medical information through their healthcare providers.

  • GlobeNewswire3 months ago

    Predictive Technology Group Submits Application to List on NASDAQ

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces submission of its application to list its common stock on NASDAQ. The Company’s management has completed the application and submitted the request to list Predictive on The NASDAQ Exchange. The listing of the Company’s common shares remains subject to the approval of NASDAQ and the satisfaction of all applicable listing standards. Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories.

  • GlobeNewswire3 months ago

    Predictive Technology Group Completes Integration of Taueret Laboratories and Inception Dx into its Subsidiary, Predictive Laboratories

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that it has completed the integration of two acquired DNA laboratories into the Predictive subsidiary, Predicative Laboratories. Based in Salt Lake City, Predictive Laboratories runs a state-of-the-art molecular laboratory initially focusing on human infertility and women's health.

  • GlobeNewswire3 months ago

    Predictive Technology Group Names Christine Seward Senior Vice President of Sales and Marketing of Predictive Laboratories

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Christine Seward, MS, CGC, has joined Predictive Laboratories as Senior Vice President of Sales and Marketing. Ms. Seward brings extensive experience commercializing molecular diagnostics including products in the reproductive space from her 16-year tenure at Myriad Genetics.

  • GlobeNewswire3 months ago

    Predictive Technology Group Integrates Sales and Marketing Team from FlagshipHealth Group

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that it has integrated the sales and marketing team from FlagshipHealth Group, a Predictive consultant contractor. This strategic move is expected to ensure control and growth of sales and marketing efforts for its subsidiary companies, Predictive Biotech and Predictive Laboratories. FlagshipHealth Group, a Minneapolis-based provider of strategic sales and consulting services for the healthcare industry, has worked with Predictive Technology Group subsidiary companies to provide guidance and early development of their commercialization strategies.

  • GlobeNewswire4 months ago

    Predictive Technology Group Announces Lab Expansion and New Research and Development Facility for Subsidiary, Predictive Biotech

    SALT LAKE CITY, March 28, 2019 -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision.

  • GlobeNewswire4 months ago

    Predictive Technology Group Completes Acquisition of Taueret Laboratories

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces it has completed the acquisition of Taueret Laboratories, LLC, a clinical and research molecular laboratory, for $9,747,800, with $1,200,000 paid at closing in the form of the Company’s restricted common stock and $8,547,800 to be paid on or before December 31, 2020, subject to certain conditions. Taueret Laboratories will join Predictive Technology Group’s newest subsidiary Predictive Laboratories. “With the completion of this acquisition and addition of a highly experienced staff, we have formed an unparalleled molecular clinical and research facility to support our objectives of commercializing novel diagnostics based on predictive analytics and extensive genetic information,” said Bradley C. Robinson, CEO of Predictive Technology Group.

  • GlobeNewswire4 months ago

    Predictive Technology Group Names Senator Orrin G. Hatch and Ronald Barhorst to Its Board of Directors

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces the appointment of Senator Orrin G. Hatch and Ronald Barhorst to the company’s Board of Directors, effective immediately. Senator Hatch brings experience from his seven terms as a U.S. Senator including serving as a member and/or chair of various U.S. Senate committees. Mr. Barhorst brings 25 years of experience as a senior executive in the financial services industry and has served as an advisor to the company or its predecessors for nearly 10 years.

  • GlobeNewswire4 months ago

    Juneau Biosciences Gives Four Presentations at the 66th Annual Meeting of the Society for Reproductive Investigation (SRI)

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Juneau Biosciences is delivering four scientific presentations at the 66th Annual Meeting of the Society for Reproductive Investigation (SRI), which is being held from Tuesday, March 12th to Saturday, March, 16th in Paris, France.  Predictive Technology Group inlicensed the technology supporting its ARTGuide® Test for endometriosis and other genetic causes of infertility from Juneau and is the company’s largest shareholder.

  • GlobeNewswire4 months ago

    Juneau Biosciences to Present at the 66th Annual Meeting of the Society for Reproductive Investigation (SRI)

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Juneau Biosciences will deliver four scienctific presentations at the 66th Annual Meeting of the Society for Reproductive Investigation (SRI), which will be held from Tuesday, March 12th to Saturday, March, 16th in Paris, France.  Predictive Technology Group inlicensed the technology supporting its ARTGuide® Test for endometriosis and other genetic causes of infertility from Juneau and is the company’s largest shareholder.

  • GlobeNewswire4 months ago

    Predictive Technology Group Sponsors 5th Annual Perinatal Stem Cell Society Congress

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that its subsidiary Predictive Biotech sponsored the 5th Annual Perinatal Stem Cell Society Congress held February 28 through March 1, 2019 in Salt Lake City.  Predictive Biotech uses perinatal tissue to produce human cell and tissue products. “We are pleased that Predictive has joined the perinatal society as a platinum sponsor for the second year.

  • GlobeNewswire5 months ago

    Predictive Technology Group Names Jay M. Moyes to Its Board of Directors

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.

  • GlobeNewswire5 months ago

    Predictive Technology Group Reports Second Quarter Fiscal 2019 Financial

    SALT LAKE CITY, Feb. 15, 2019 -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic.

  • GlobeNewswire8 months ago

    Predictive Technology Group to Present at 11th Annual LD Micro Main Event Conference on December 4

    SALT LAKE CITY, Nov. 27, 2018 -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a life-sciences technology company, announces that Bradley Robinson, President and CEO,.

  • GlobeNewswire9 months ago

    Predictive Technology Group Appoints Industry Veteran John E. Sorrentino as Chairman

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that John E. Sorrentino has been named Chairman of the Board in addition to his role as Chair of the Predictive Scientific Advisory Board. Sorrentino has more than 35 years of senior management experience in the life sciences industry and serves as Vice President and Chief Operating Officer of Pfizer Vaccine Research and Development.